Are you conducting or planning a clinical trial focusing on the treatment of COVID-19? With decades of experience in BioAnalytical testing, including HPLC/MS/MS, Quinta-Analytica are well placed to support you.

We provide reliable and accurate data on active ingredient content in clinical trial participants, allowing you to not only assess compliance with the treatment regime, but most importantly determine the relationship between drug concentration and response to the treatment.

Quinta-Analytica is a GLP and GCP certified testing facility, with a strong focus on the bio-analytical determination of the content of small molecules in biological matrices – both human and animal.  We also offer full analyses of parent drug content and/or its important metabolites.

Our team possesses decades of experience in the gold standard for such analyses, the HPLC/MS/MS technique. Furthermore, we have at our disposal equipment and methodologies for determining the content of large molecules, if required.

With constant supervision by our quality assurance department in accordance with legal regulations and international standards, we are able to compile a bioanalytical protocol, develop and validate the analytical method, receive samples sent by individual centers, and perform our own determinations – all based on your clinical trial protocol.

We can also provide the obtained results in the form of an analytical report, process them and perform a pharmacokinetic or statistical evaluation, all per your particular needs and requirements.

Get in touch today and let’s discuss the most suitable solution for your trial.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.